SCHEMBL13765787

SCHEMBL13765787

CC(=O)Nc1cncc(C(C)(C)C)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.44
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44
BRAF P15056 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
ADORA3 P0DMS8 5/20 0.40
PIK3C3 Q8NEB9 2/20 0.39
PTK2 Q05397 1/20 0.39
LMNA P02545 1/20 0.38
ADORA2B P29275 1/20 0.37
ADORA1 P30542 1/20 0.37
CYP1A2 P05177 1/20 0.37
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
NFKB1 P19838 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13765794 0.83 ALDH1A1 (0.46) BRAFALDH1A1GAATDP1NPC1
SCHEMBL4413746 0.82 KDM4E (0.53) KDM4EHSP90AA1HSP90AB1BRAFL3MBTL1
SCHEMBL13765784 0.80 ATAD2 (0.50) L3MBTL1ADORA2BCYP1A2RAB9A
SCHEMBL1431348 0.76 KDM4E (0.47) KDM4EHSP90AA1HSP90AB1BRAFL3MBTL1
SCHEMBL10183380 0.75 KDM4E (0.57) KDM4EHSP90AA1HSP90AB1ADORA3LMNA
SCHEMBL13765788 0.74 FOS (0.31) NFKB1NFKB2RELA
SCHEMBL21827821 0.74 KDM4E (0.46) KDM4EHSP90AA1HSP90AB1BRAFL3MBTL1
SCHEMBL21928148 0.74 KDM4E (0.46) KDM4EHSP90AA1HSP90AB1BRAFL3MBTL1
SCHEMBL6284192 0.74 PTK2 (0.49) KDM4EHSP90AA1HSP90AB1BRAFL3MBTL1
SCHEMBL19706555 0.74 KDM4E (0.46) KDM4EHSP90AA1HSP90AB1BRAFL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220235032-A1 BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2022-07-28 US disclosed
US-8461167-B2 Acetylenic heteroaryl compounds ARIAD PHARMACEUTICALS, INC. (US) 2013-06-11 US disclosed
US-20090176781-A1 Acetylenic Heteroaryl Compounds ARIAD PHARMACEUTICALS, INC. 2009-07-09 US disclosed
WO-2007133560-A2 ACETYLENIC HETEROARYL COMPOUNDS ARIAD PHARMACEUTICALS, INC. (US) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176781-A1 Acetylenic Heteroaryl Compounds NAT1, AADAC, ACACA KDM4E 3538/4885HSP90AA1 2774/4885HSP90AB1 2435/4885
US-20220235032-A1 BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF RIPK1, RIPK4, RIPK3 KDM4E 2795/4885HSP90AA1 3343/4885HSP90AB1 3162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.